Five early-career Fred Hutch/UW researchers received prestigious Young Investigator Awards from Conquer Cancer, the ASCO Foundation during this year's annual meeting of the American Society of ...

Zanubrutinib shows durable efficacy in CLL/SLL with 17p deletions, according to 5-year SEQUOIA trial data.

Over time, some follicular lymphomas can turn into a fast-growing diffuse large B-cell lymphoma. Chronic lymphocytic leukemia (CLL) /small lymphocytic lymphoma (SLL) CLL and SLL are closely related ...

STARLIGHT-1 trial has dosed the first patient in the second cohort of the study evaluating EB103 in advanced B-cell ...

DelveInsight’s Natural Killer (NK)-Cell Lymphoma Pipeline report depicts a robust space with 100+ active players working to develop 140+ pipeline therapies for Natural Killer (NK)-Cell Lymphoma ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New ...

NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Autolus Therapeutics' autologous CD19-directed CAR T-cell therapy Aucatzyl ...

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and ...

Analyzing DNA methylation patterns in leukemic cells is helping doctors better assess risk and tailor treatments, making ...

BeiGene , Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Lt ...

in chronic lymphocytic leukemia (CLL) progression, according to a study published in Biomarker Research. The inhibition of FAO impaired CLL cell survival and synergistically enhanced the efficacy ...